Plus, the tariff refund portal just opened. These retailers stand to benefit the most.
Plus, the "splashy" index that's up 179% to the S&P 500's 33%...
Plus, the contrarian AI call the financials actually support...
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Plus, biotech just landed its biggest IPO in years...
Plus, the mega-layoff era is officially here...
Plus, why 1 in 4 Americans are turning to AI for health advice...
Why ZENA could become the small-cap powerhouse leading America's AI-driven counter-drone revolution.
Plus, is Kevin Warsh the next Nancy Pelosi?
Plus, why tariff refunds won't be heading to consumers...
Plus, three high-yield dividends worth watching...
Plus, the AI cold war just got a new alliance...
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Plus, this emergency got Powell and Bessent on the same page...
Plus, Michael Burry turns... bullish?
Plus, an alleged insider trader is out...
Plus, the next wave of weight-loss drugs...
Plus, a big barrier for OpenAI's IPO...
Plus, the next class of Dividend Aristocrats...
Plus, the robots just took another job...
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
Plus, promising jobs data? In this economy?
Plus, a big change is coming (back) to Hershey...
SMX emerges as a critical shield for US national security as conflict threatens rare earth flows.
Plus, will AI decide the Supreme Court's next case?
